Company News - VC and PE investment business - Medical and health professional investment - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 04 - 03

Yewei Medical Completes Nearly 100M RMB Series B to Strengthen Cardiovascular Surgery Footprint

Recently, Beijing Yewei Medical Technology Co., Ltd. ("Yewei Medical") announced the completion of a nearly 100 million RMB equity financing round. This round was led by Fenix Capital, with participation from Beishang Capital and Bohai Chuangfu, and Kaicheng Capital serving as the exclusive financial advisor.This marks Yewei Medical's second substantial financing round within the year, fully reflecting the capital market's strong recognition of the company's development trajectory. Supported by this financing, Yewei Medical will continue to comprehensively strengthen its ...

浏览次数：3

查看详情>>

发布时间: 2026 - 03 - 31

Monthly Health Digest | March 2026

PrefaceIn March, the industry grand event BIOCHINA 2026 kicked off in Suzhou. Mr. Zhu Pai, CEO of Efung Capital, was invited to attend and engaged in in-depth dialogue with industry peers on March 13 at the roundtable forum "LP-GP Ecosystem Encirclement: Synergizing Policy, Capital, and Innovation." Meanwhile, Efung Capital's portfolio companies also shone brightly at the conference, with companies such as IASO Bio making significant appearances, collectively showcasing the cutting-edge power of Chinese innovative drug companies.Beyond the conference, many of Efung ...

浏览次数：4

查看详情>>

发布时间: 2026 - 03 - 30

China's First and World's First Recombinant Type A Botulinum Toxin Approved for Market

On March 25, the National Medical Products Administration (NMPA) officially announced that the Recombinant Type A Botulinum Toxin for Injection (National Drug Approval No. S20260019), developed by Chongqing Yuyan Pharmaceutical Co., Ltd. (a subsidiary of MingMed), has been approved for market. This is China's first and the world's first recombinant technology-produced Type A botulinum toxin, marking a core technological breakthrough in the botulinum toxin field for China and breaking the long-standing monopoly of imported products.Unlike traditional botulinum toxin fermentation process...

浏览次数：5

查看详情>>

发布时间: 2026 - 03 - 25

Frontier Biotechnologies Enters Exclusive License Agreement with GSK for siRNA Pipeline Products

Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New Drug (IND) application stage, while the other is a preclinical candidate.This agreement highlights the Company’s expertise in early-stage siRNA drug discovery and development, marking a significant m...

浏览次数：5

查看详情>>